AE Wealth Management LLC Boosts Stock Position in GlaxoSmithKline plc (NYSE:GSK)

view original post

AE Wealth Management LLC boosted its holdings in GlaxoSmithKline plc (NYSE:GSK) by 29.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 84,019 shares of the pharmaceutical company’s stock after purchasing an additional 18,896 shares during the period. AE Wealth Management LLC’s holdings in GlaxoSmithKline were worth $3,210,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Dodge & Cox boosted its position in GlaxoSmithKline by 0.3% in the second quarter. Dodge & Cox now owns 88,209,189 shares of the pharmaceutical company’s stock worth $3,512,490,000 after purchasing an additional 261,944 shares during the last quarter. Capital International Investors lifted its position in shares of GlaxoSmithKline by 14.0% during the 2nd quarter. Capital International Investors now owns 22,676,745 shares of the pharmaceutical company’s stock valued at $902,988,000 after buying an additional 2,787,034 shares during the last quarter. Fisher Asset Management LLC lifted its position in shares of GlaxoSmithKline by 1.6% during the 3rd quarter. Fisher Asset Management LLC now owns 17,830,400 shares of the pharmaceutical company’s stock valued at $681,300,000 after buying an additional 282,409 shares during the last quarter. Black Creek Investment Management Inc. lifted its position in shares of GlaxoSmithKline by 4.8% during the 2nd quarter. Black Creek Investment Management Inc. now owns 9,086,870 shares of the pharmaceutical company’s stock valued at $361,839,000 after buying an additional 418,371 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of GlaxoSmithKline by 3.4% during the 2nd quarter. Renaissance Technologies LLC now owns 9,061,321 shares of the pharmaceutical company’s stock valued at $360,822,000 after buying an additional 298,300 shares during the last quarter. 11.86% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have recently commented on GSK. Morgan Stanley reaffirmed an “equal weight” rating on shares of GlaxoSmithKline in a research report on Wednesday, November 3rd. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, November 1st. Barclays raised GlaxoSmithKline from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 5th. UBS Group reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, November 8th. Finally, Berenberg Bank reiterated a “buy” rating on shares of GlaxoSmithKline in a research note on Wednesday, November 24th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $41.00.

NYSE:GSK opened at $43.76 on Friday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.54 and a current ratio of 0.81. GlaxoSmithKline plc has a 52-week low of $33.53 and a 52-week high of $44.09. The firm has a market cap of $117.83 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 2.46 and a beta of 0.74. The business’s fifty day moving average is $42.08 and its 200 day moving average is $40.71.

GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, October 27th. The pharmaceutical company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.80 by $0.21. The company had revenue of $12.51 billion for the quarter, compared to analyst estimates of $11.92 billion. GlaxoSmithKline had a return on equity of 26.27% and a net margin of 13.01%. Equities analysts predict that GlaxoSmithKline plc will post 3.05 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 13th. Shareholders of record on Friday, November 19th will be paid a $0.5234 dividend. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.52. This represents a $2.09 dividend on an annualized basis and a yield of 4.78%. The ex-dividend date of this dividend is Thursday, November 18th. GlaxoSmithKline’s dividend payout ratio is currently 87.29%.

GlaxoSmithKline Profile

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.

Recommended Story: What is an overbought condition?

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Want More Great Investing Ideas?